Guardant Health Inc. (NASDAQ:GH) saw a downside of -1.74% to $36.20 after subtracting -$0.64 on Wednesday. The 5-day average trading volume is 1,592,022 shares of the company’s common stock. It has gained $38.00 in the past week and touched a new high 3 times within the past 5 days. An average of 1,340,596 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,929,062.
GH’s 1-month performance is -5.04% or -$0.93 on its low of $34.98 reached on 08/03/23. The company’s shares have touched a 52-week low of $20.67 and high of $62.75, with the stock’s rally to the 52-week high happening on 07/27/23. YTD, GH has achieved 33.09% or $9.06 and has reached a new high 20 times. However, the current price is down -42.31% from the 52-week high price.
Insider Transactions
GH stock investors last saw insider trading activity on Jun 15.Joyce Meghan V. (Director) most recently sold 2,766 shares at $37.55 per share on Jun 15. This transaction cost the insider $103,863. Chief Information Officer, Kalia Kumud, sold 6,500 shares at a price of $31.92 on Mar 03. Then, on Nov 15, Chief Information Officer Kalia Kumud sold 3,125 shares at a price of $51.87 per share. This transaction amounted to $162,082.
Valuation Metrics
GH stock has a beta of 0.87. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 8.26.
Guardant Health Inc.’s quick ratio for the period ended June 29 was 5.20, with the current ratio over the same period at 5.40. In terms of profitability, the gross margin trailing 12 months is 63.20%. The trailing 12-month EBITDA margin is -110.98%. The firm’s gross profit as reported stood at $293.21 million against revenue of $449.54 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Guardant Health Inc.’s cash and short-term investments amounted to $953.78 million against total debt of $1.36 billion. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -215.28% to -$72.77 million, while revenue of -$133.53 million was -83.5% off the previous quarter. Analysts expected GH to announce -$1.18 per share in earnings in its latest quarter, but it posted -$0.67, representing a 43.20% surprise. EBITDA for the quarter stood at more than -$110.42 million. GH stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.55 billion, with total debt at $1.36 billion. Shareholders hold equity totaling $117.69 million.
Let’s look briefly at Guardant Health Inc. (GH) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 42.65% to suggest the stock is trending Neutral, with historical volatility in this time period at 52.15%.
The stock’s 5-day moving average is $36.79, reflecting a +0.33% or $0.12 change from its current price. GH is currently trading -3.97% above its 20-day SMA, +28.31% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +29.13% and SMA200 by-19.60%.
Stochastic %K and %D was 42.88% and 47.47% and the average true range (ATR) pointed at 1.59. The RSI (14) points at 46.63%, while the 14-day stochastic is at 29.09% with the period’s ATR at 1.55. The stock’s 9-day MACD Oscillator is pointing at -0.46 and -0.65 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for GH stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate GH as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 17 have offered a “buy” rating.
What is GH’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $40.00 and a high of $85.00, with their median price target at $53.00. Looking at these predictions, the average price target given by analysts is for Guardant Health Inc. (GH) stock is $55.24.
